As the prevalence of both diabetes and cancer rises, and with the increasing use of newer glucose-lowering medications like sodium-glucose co-transporter-2 (SGLT2) inhibitors, which increase the risk of DKA, it is crucial to maintain awareness of these complications in cancer patients. This evidence concerns the gene SLC5A2 and diabetes mellitus.